Surgical Oncologist and former Director of Greater Manchester Pathway Board for Breast
Consultant histopathologist at Wythenshawe Hospital, Manchester University NHS Foundation Trust
Research lead for breast pathology at the department of pathology, Wythenshawe Hospital.
Named pathologist for ATNEC clinical trial at the Nightingale Centre, Wythenshawe Hospital.
Reviews and marks triple negative breast tumour samples for research and PhD projects at CRUK, Manchester.
Research interests include intraoperative painting of breast margins by surgeons.
Consultant Clinical Oncologist at The Christie NHS Foundation Trust
Specialises in treatment of breast cancer.
Breast radiotherapy research and technical lead at The Christie.
Research interests include breast radiotherapy and patient reported outcomes.
Medical Physicist and Senior Lecturer in Adaptive Radiotherapy
Marianne is Marianne is Senior lecturer in the Radiotherapy-Related Research Group at the University of Manchester/The Christie Hospital.
She is also an external Associate Professor at Oxford University and the University of Copenhagen, and member of the teaching faculty of the European Society for Radiotherapy and Oncology.
Dr Marianne Camille Aznar | The University of Manchester
Senior Lecturer in Medicinal Chemistry
The Butterworth group work on applying synthetic and biological chemistry to study and solve biological problems of relevance to human health. One key theme of this work is the utilisation of the cell’s biological machinery to selectively activate molecules to kill cancer cells with specific mutations, or to selectively reprogram the activity of key immune cells. We have several breast cancer focussed collaborations with biomedical researchers and clinicians at Manchester and beyond. These include projects with funding from the Wellcome Trust (~£5 million seeding drug discovery award, looking at novel kinase inhibitors in TNBC), CRUK and MRC CiC (together ~£400k, looking at novel kinase modulators as immune-oncology agents in TNBC with Katie Finegan).
Phamacy Lecturer in Cancer Biology and Therapy
My research group investigates the mechanisms by which mitogen-activated protein kinases (MAPK) regulate cancer biology and therapeutic response, with a particular focus on triple-negative breast cancer. Using a combination of established pharmacological inhibitors, novel and exclusive pre-clinical mouse models, human samples and in vivo techniques, my group’s central aim is to translate findings at the molecular level into valid therapeutic avenues and/or biomarkers of cancer progression and therapy response. Current projects include studies into ERK5 and MEK5 inhibitors, and further characterisation of the role of ERK5 in inflammatory responses and metastatic spread.
Senior Research Fellow in Immune Oncology
I am a Senior Lecturer within the Targeted Therapy Group at the University of Manchester. My research interests lie in the field of onco-immunology. I have a long-standing interest in developing novel radiation and immunotherapy combinations for the treatment of cancer, primarily using monoclonal antibodies (mAb) targeting various immune receptors to enhance the activity of tumour-specific T-cell priming and function following radiotherapy. More recently, my research has focussed on evaluating the induction of immunogenic cell death (ICD) following radiation therapy and assessing the impact this has on therapeutic outcome during combination approaches. This involves investigation of numerous damage-associated molecular patterns (DAMP), and in particular, the role of high mobility group box 1 (HMGB1) in driving T-cell responses post-radiation and chemotherapy. I am interested in various apsects of HMGB1 biology including the kinetics and mechanism of release; redox staus and post-translational modification; potential utility as a biomarker of response; and the ability to promote tumour repopulation and growth. I am also interested in the mechanism of action of anti-CD20 mAb, especially type II mAb which induce direct cell death in a variety of B-cell malignancies and evaluating the immunological consequences of CD20-induced death, including DAMP release. Potential combination approaches to enhance cell death are also being explored.
Roger Hunt has been a consultant histopathologist at Wythenshawe Hospital, Manchester since 2011. His special interests include breast pathology, particularly the immunohistochemistry of prognostic and predictive markers. Roger actively supports various aspects of ongoing clinical research at Wythenshawe and has a strong background in multi-professional medical education.
Roger was the Chair of the Greater Manchester Breast Clinical Subgroup from 2007-9. He is a member of the UK NEQAS Immunohistochemistry Scientific Advisory Board and has advised on the revision of national NICE guidelines for early and locally advanced breast cancer and also cancers of unknown primary origin.
Consultant Radiologist, Manchester University NHS Foundation Trust (MFT)
Gillian Hutchison has been a consultant breast radiologist since 2008, first working in the Bolton breast unit and currently in the Nightingale Breast Unit at Wythenshawe Hospital, MFT since April 2016. As Director of Breast Screening for Manchester, her main areas of interest are in early detection of breast cancer and personalisation of breast screening, but working in a busy screening and symptomatic service she participates in local, national and international breast studies. The breast screening unit was part of the Age Extension trial. She has contributed to several breast studies including Mammo 50, Sloane, LORIS, Forget Me Not, and more recently BRAID and Compulse (for which she is PI). Prior to commencing her career in Breast Radiology she investigated factors affecting outcomes in cervical and anal carcinomas and the relationship to hypoxia and treatment as well as the links with HPV and obtained her MD from the University of Manchester in 2009. Aside from Breast Radiology she also has a sub-speciality interest in Fetal Medicine/Imaging.
Professor of Chronobiology
We study 24-hour biological clocks in ageing and age-related diseases. Circadian rhythms are the endogenous 24-hour cycles governing nearly all aspects of our physiology and behaviour, including many fundamental cellular functions. One key area in the lab is to investigate the role of circadian clocks in the biology and pathogenesis of breast cancer. Our earlier work has discovered cell-intrinsic circadian clocks in mammary stem cells and epithelia, which control the expression of hundreds of breast tissue-specific rhythmic genes and respond to the cellular microenvironment and tissue stiffness (Blakeman et al, Breast Cancer Res 2016; Yang et al, Nat Comms 2017; Broadberry et al, Breast Cancer Res 2018; Williams et al, J Cell Sci 2018; Streuli and Meng, J Cell Sci 2019). More recently, we have used clinical breast cancer samples, circadian time series “-omics”, artificial intelligence and machine learning algorithms and quantitative live imaging to investigate the molecular links between circadian clock disruptions and breast cancer development. We are also interested in a “circadian medicine” approach to tailor existing therapies according to the patient’s internal body clocks for better clinical outcomes.
Research in this group has been supported by the MRC, Breast Cancer Now, BBSRC sLoLa, Wellcome Trust and industries. Our research has received extensive media coverage including BBC Breakfast, BBC Radio Stoke, BBC Radio 5, BBC Radio Manchester.
Professor of Developmental Neuroscience & Wellcome Trust Senior Research Fellow
During development, cells transition from a progenitor state to differentiation with defined timing, or to quiescence from which they may be reactivated. Understanding how such transitions and their timing are regulated is key in understanding how tissues are built, maintained, repaired or subverted in disease.
In recent years, our understanding of how cells make cell state transitions has been transformed by the application of single cell molecular technology that revealed a large degree of non-genetic heterogeneity in seemingly homogeneous populations of cells. In neural progenitors, single cell imaging with unstable reporters has revealed asynchronous pulsatile fluctuations in regulatory gene expression, which is masked by static measurements of population averages. Thus, cell fate transitions may not be driven simply by genes being turned on or off, but by a change in the dynamics of gene expression for example, from fluctuating or pulsatile expression to a more stable state.
I am a Consultant Histopathologist with 15 years’ experience working at Manchester Foundation Trust Wythenshawe Hospital, subspecialising in breast pathology. Our unit reports over 1000 breast cancers per year, being one of the largest in the UK. My work is predominantly clinical, including work for the NHS Breast Screening programme, for which I am one of the North of England’s Clinical Professional Advisors. My main research interests are in the prevention of breast cancer, offering histopathological advice to surgeons and oncologists working in this field.
Consultant Oncoplastic Breast Surgeon and Clinical Director for Breast Surgery, North Manchester General Hospital
Professor of Experimental Therapeutics
Kaye currently leads a multi-disciplinary team who work towards producing proof of concept data to support the translation of novel anti-cancer approaches into patients. She has specific interests in the tumour microenvironment, particularly the condition of hypoxia, and how to therapeutically target this to improve cancer outcomes. Kaye also has a keen interest in the use of molecular targeted and/or biological therapies in combination with radiation treatment. In particular she has investigated the impact of novel agents on the underlying mechanisms that govern radiation response to enable their optimal application in a clinical radiotherapy context. These studies have underpinned ongoing clinical trials within The Christie, Manchester, and nationally that are showing positive patient benefit. Kaye has a lead role in the development of pre-clinical imaging for oncology applications within the Manchester Cancer Research Centre. The focus here is to develop, validate and apply image derived biomarkers to assess changes in tumour biology and therapeutic response.
Wellcome Trust/Royal Society Sir Henry Dale Fellow
The tissues of our bodies are extremely complicated at the cellular level, comprising different types of cells arranged with precise geometry. Within this complex system, the direction in which a cell divides is a crucial tool used to shape tissues and determine cell fate. Defects in division orientation have lethal consequences: they cause failures in embryonic development and are associated with cancer.
To coordinate cell division across a tissue, cells must be able to “read” their external cellular environment and orient their division accordingly. The mechanisms that control this remain unclear, but we know that cues from the extracellular matrix play a vital role. These cues must be fed to a cellular structure called the mitotic spindle, the positioning of which determines cell division orientation. Understanding the mechanisms used by the cell to correctly position the spindle is a key focus of our lab. In particular, we are investigating how molecular forces are balanced inside the cell to position the mitotic spindle and how these internal mechanisms are linked to the external cellular environment in order to coordinate spindle orientation across a tissue.
CRUK MI Group Leader in Immuno-Oncology
Dr Zelenay obtained his undergraduate degree in biology from the University of Buenos Aires in 2002. As a student he worked on DNA vaccines in the laboratory of Juan Fló. He then undertook his Ph.D. in Immunology at the Institute Gulbenkian of Science in Portugal where he studied regulatory T cells, working with Jocelyne Demengeot and Antonio Coutinho. In 2008, he joined the group of Caetano Reis e Sousa at the Cancer Research UK (CRUK) London Research Institute and later at The Francis Crick Institute, where he was awarded Marie Curie and EMBO fellowships to investigate innate immune receptors and signaling pathways that trigger dendritic cell activation and drive T cell responses against viruses or tumours. In 2015, Dr. Zelenay joined the CRUK Manchester Institute as a Junior Group Leader to form the Cancer Inflammation and Immunity Group. His group focuses on understanding the underlying mechanisms that mediate cancer-inhibitory versus tumour-promoting inflammation in order to design new therapies for cancer patients. In 2017, he received the CRUK Future Leaders in Cancer Research Prize.